EA201190062A1 - Производные пиримидинкарбоксамида в качестве ингибиторов syk-киназы - Google Patents

Производные пиримидинкарбоксамида в качестве ингибиторов syk-киназы

Info

Publication number
EA201190062A1
EA201190062A1 EA201190062A EA201190062A EA201190062A1 EA 201190062 A1 EA201190062 A1 EA 201190062A1 EA 201190062 A EA201190062 A EA 201190062A EA 201190062 A EA201190062 A EA 201190062A EA 201190062 A1 EA201190062 A1 EA 201190062A1
Authority
EA
Eurasian Patent Office
Prior art keywords
syk
pyrimidincarboxamide
derivatives
kinase inhibitors
treatment
Prior art date
Application number
EA201190062A
Other languages
English (en)
Inventor
Фрэнсис Льюис Аткинсон
Випулкумар Кантибхай Пател
Original Assignee
Глаксо Груп Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Глаксо Груп Лимитед filed Critical Глаксо Груп Лимитед
Publication of EA201190062A1 publication Critical patent/EA201190062A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Соединение формулы (I) или соль, предпочтительно фармацевтически приемлемая соль, является ингибитором селезеночной тирозинкиназы (SYK) и поэтому потенциально полезно в лечении заболеваний, возникающих в результате неприемлемой активации тучных клеток, например аллергических и воспалительных заболеваний, а также потенциально полезно в лечении раковых заболеваний, особенно гематологических злокачественных новообразований
EA201190062A 2009-01-13 2010-01-11 Производные пиримидинкарбоксамида в качестве ингибиторов syk-киназы EA201190062A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14421009P 2009-01-13 2009-01-13
PCT/EP2010/050228 WO2010097248A1 (en) 2009-01-13 2010-01-11 Pyrimidinecarboxamide derivatives as inhibitors of syk kinase

Publications (1)

Publication Number Publication Date
EA201190062A1 true EA201190062A1 (ru) 2012-02-28

Family

ID=41694078

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201190062A EA201190062A1 (ru) 2009-01-13 2010-01-11 Производные пиримидинкарбоксамида в качестве ингибиторов syk-киназы

Country Status (15)

Country Link
US (1) US8470835B2 (ru)
EP (1) EP2376481B1 (ru)
JP (1) JP2012515148A (ru)
KR (1) KR20110100679A (ru)
CN (1) CN102348707A (ru)
AU (1) AU2010219097A1 (ru)
BR (1) BRPI1006162A2 (ru)
CA (1) CA2749403A1 (ru)
EA (1) EA201190062A1 (ru)
ES (1) ES2433109T3 (ru)
IL (1) IL213906A0 (ru)
MX (1) MX2011007499A (ru)
SG (1) SG172943A1 (ru)
WO (1) WO2010097248A1 (ru)
ZA (1) ZA201104949B (ru)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
ES2546502T3 (es) 2008-04-16 2015-09-24 Portola Pharmaceuticals, Inc. 2,6-Diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o JAK quinasas
GB201007203D0 (en) 2010-04-29 2010-06-16 Glaxo Group Ltd Novel compounds
JP5744021B2 (ja) 2010-06-30 2015-07-01 富士フイルム株式会社 新規なニコチンアミド誘導体またはその塩
CN103282352B (zh) * 2010-11-01 2016-08-10 波托拉医药品公司 作为syk调节剂的苯甲酰胺类和烟酰胺类
CA2818712C (en) 2010-11-24 2020-11-10 Government Of The U.S.A. Represented By The Secretary, Dept. Of Health & Human Services Compositions and methods for treating or preventing lupus
US10017762B2 (en) 2010-11-24 2018-07-10 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Compositions and methods for treating or preventing lupus
EP2489663A1 (en) 2011-02-16 2012-08-22 Almirall, S.A. Compounds as syk kinase inhibitors
LT2699553T (lt) 2011-04-22 2024-02-12 Signal Pharmaceuticals, Llc Pakeistas diaminokarboksamidas ir diaminokarbonitrilo pirimidinai, jų kompozicijos ir gydymo būdai
US9006444B2 (en) * 2011-10-05 2015-04-14 Merck Sharp & Dohme Corp. Phenyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors
EP2763975B1 (en) 2011-10-05 2016-04-06 Merck Sharp & Dohme Corp. 3-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors
SG11201402570QA (en) 2011-11-23 2014-06-27 Portola Pharm Inc Pyrazine kinase inhibitors
WO2013078468A1 (en) * 2011-11-23 2013-05-30 Portola Pharmaceuticals, Inc. Selective kinase inhibitors
WO2013099041A1 (ja) 2011-12-28 2013-07-04 富士フイルム株式会社 新規なニコチンアミド誘導体またはその塩
AR090650A1 (es) 2012-04-12 2014-11-26 Alcon Res Ltd Tratamiento para respuestas inflamatorias inducidas por microbios en el ojo
WO2014051654A2 (en) * 2012-09-27 2014-04-03 Portola Pharmaceuticals, Inc. Bicyclic oxa-lactam kinase inhibitors
WO2014071109A1 (en) 2012-11-01 2014-05-08 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
EP2970194A1 (en) 2013-03-15 2016-01-20 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
ES2834638T3 (es) 2013-05-30 2021-06-18 Infinity Pharmaceuticals Inc Tratamiento de cánceres usando moduladores de isoforma de PI3 cinasa
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
BR112016007467B1 (pt) 2013-10-04 2022-09-20 Infinity Pharmaceuticals, Inc Compostos heterocíclicos e usos dos mesmos
WO2015061204A1 (en) 2013-10-21 2015-04-30 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
NZ715903A (en) * 2014-01-30 2017-06-30 Signal Pharm Llc Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
CN106456628A (zh) 2014-03-19 2017-02-22 无限药品股份有限公司 用于治疗PI3K‑γ介导的障碍的杂环化合物
WO2015160986A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP6762940B2 (ja) 2014-12-16 2020-09-30 シグナル ファーマシューティカルズ，エルエルシー ２−（ｔｅｒｔ−ブチルアミノ）−４−（（１Ｒ，３Ｒ，４Ｒ）−３−ヒドロキシ−４−メチルシクロヘキシルアミノ）−ピリミジン−５−カルボキサミドの製剤
WO2016100308A1 (en) 2014-12-16 2016-06-23 Signal Pharmaceuticals, Llc Methods for measurement of inhibition of c-jun n-terminal kinase in skin
WO2016123291A1 (en) 2015-01-29 2016-08-04 Signal Pharmaceuticals, Llc Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
AU2016297784B2 (en) 2015-07-24 2020-12-24 Celgene Corporation Methods of synthesis of (1R,2R,5R)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein
RU2018106663A (ru) 2015-07-24 2019-08-26 Глэксо Груп Лимитед Лечение витилиго
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3474856B1 (en) 2016-06-24 2022-09-14 Infinity Pharmaceuticals, Inc. Combination therapies
US10111882B2 (en) 2016-09-14 2018-10-30 Gilead Sciences, Inc. SYK inhibitors
TW201822764A (zh) 2016-09-14 2018-07-01 美商基利科學股份有限公司 Syk抑制劑
WO2018195471A1 (en) 2017-04-21 2018-10-25 Gilead Sciences, Inc. Syk inhibitors in combination with hypomethylating agents
BR112021018168B1 (pt) 2019-03-21 2023-11-28 Onxeo Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
AU2020378630A1 (en) 2019-11-08 2022-05-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN116209441A (zh) 2020-09-18 2023-06-02 住友制药株式会社 新型胺衍生物

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1201114A (en) 1980-02-15 1986-02-25 Gordon H. Phillipps Androstane carbothioates
AU570439B2 (en) 1983-03-28 1988-03-17 Compression Labs, Inc. A combined intraframe and interframe transform coding system
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
WO1999031073A1 (fr) * 1997-12-15 1999-06-24 Yamanouchi Pharmaceutical Co., Ltd. Nouveaux derives de pyrimidine-5-carboxamide
AU760598B2 (en) 1997-12-17 2003-05-15 Carnegie Wave Energy Limited Rigidized trimethine cyanine dyes
US5989255A (en) 1998-08-06 1999-11-23 Smith & Nephew Orthopaedic done screw apparatus
DE60017898T2 (de) * 1999-06-09 2006-01-12 Yamanouchi Pharmaceutical Co., Ltd. Neuartige heterocyclische carboxamidderivate
US20020052312A1 (en) 2000-05-30 2002-05-02 Reiss Theodore F. Combination therapy of chronic obstructive pulmonary disease using muscarinic receptor antagonists
BRPI0113042B8 (pt) 2000-08-05 2021-05-25 Glaxo Group Ltd composto da fórmula ou um seu solvato fisiologicamente aceitável, uso do mesmo, composição farmacêutica, formulação farmacêutica, método para o tratamento de um indivíduo humano ou animal com uma condição inflamatória e/ou alérgica, e, processo para preparar um composto ou um seu solvato
US20020193393A1 (en) 2001-03-07 2002-12-19 Michel Pairet Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors
DE10110772A1 (de) 2001-03-07 2002-09-12 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und PDE-IV-Inhibitoren
GB0118373D0 (en) 2001-07-27 2001-09-19 Glaxo Group Ltd Novel therapeutic method
GB0123951D0 (en) 2001-10-05 2001-11-28 Glaxo Group Ltd Therapies for treating respiratory diseases
WO2004035604A2 (en) 2002-10-16 2004-04-29 Millennium Pharmaceuticals, Inc. Spleen tyrosine kinase catalytic domain:crystal structure and binding pockets thereof
TWI328009B (en) 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
GB0322722D0 (en) 2003-09-27 2003-10-29 Glaxo Group Ltd Compounds
GB0322726D0 (en) 2003-09-27 2003-10-29 Glaxo Group Ltd Compounds
DK1699512T3 (da) 2003-11-03 2012-09-17 Glaxo Group Ltd Fluiddispenseringsindretning
WO2005058892A1 (en) 2003-12-19 2005-06-30 Glaxo Group Limited Pyrazolo [3,4-b] pyridine compounds, and their use as phosphodiesterase inhibitors
GB0405933D0 (en) 2004-03-16 2004-04-21 Glaxo Group Ltd Compounds
GB0405937D0 (en) 2004-03-16 2004-04-21 Glaxo Group Ltd Compounds
EP1740590A1 (en) 2004-03-16 2007-01-10 Glaxo Group Limited PYRAZOLO [3,4- b] PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS
GB0425572D0 (en) 2004-11-19 2004-12-22 Glaxo Group Ltd 1,7-Naphthyridines
GB0505621D0 (en) 2005-03-18 2005-04-27 Glaxo Group Ltd Novel compounds
GB0512246D0 (en) 2005-06-15 2005-07-27 Glaxo Group Ltd Novel pharmaceutical
EP1940835B1 (en) 2005-09-29 2011-03-30 Glaxo Group Limited Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors
GB0521563D0 (en) 2005-10-21 2005-11-30 Glaxo Group Ltd Novel compounds
DE102008007700A1 (de) * 2007-10-31 2009-05-07 Siemens Aktiengesellschaft Verfahren zur rechnergestützten Exploration von Zuständen eines technischen Systems
EP2323993B1 (en) * 2008-04-16 2015-06-03 Portola Pharmaceuticals, Inc. 2,6-diamino- pyrimidin- 5-yl-carboxamides as syk or jak kinases inhibitors

Also Published As

Publication number Publication date
CN102348707A (zh) 2012-02-08
BRPI1006162A2 (pt) 2019-09-24
US8470835B2 (en) 2013-06-25
AU2010219097A1 (en) 2011-08-04
MX2011007499A (es) 2011-08-04
IL213906A0 (en) 2011-07-31
KR20110100679A (ko) 2011-09-14
SG172943A1 (en) 2011-08-29
EP2376481A1 (en) 2011-10-19
JP2012515148A (ja) 2012-07-05
ES2433109T3 (es) 2013-12-09
CA2749403A1 (en) 2010-09-02
US20110275655A1 (en) 2011-11-10
WO2010097248A1 (en) 2010-09-02
ZA201104949B (en) 2012-12-27
EP2376481B1 (en) 2013-08-07

Similar Documents

Publication Publication Date Title
EA201190062A1 (ru) Производные пиримидинкарбоксамида в качестве ингибиторов syk-киназы
EA201290910A1 (ru) Соединения 7-(1н-пиразол-4-ил)-1,6-нафтиридина в качестве ингибиторов syk
ATE499097T1 (de) Monozyklische heterozyklen als kinase-hemmer
EA201000113A1 (ru) Пиразольные соединения
EA200800664A1 (ru) Производные пирролопиримидина в качестве ингибиторов syk
EA201391239A1 (ru) Пирроло[2,3-d]пиримидиновые производные в качестве ингибиторов тропомиозин-связанных киназ
EA201390766A1 (ru) БЕНЗОКСАЗЕПИНЫ КАК ИНГИБИТОРЫ PI3K/mTOR И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ И ПОЛУЧЕНИЯ
EA201200651A1 (ru) Гетероциклические сульфонамидные производные, применимые в качестве ингибиторов мек
EA201101435A1 (ru) Имидазотиадиазолы для применения в качестве ингибиторов киназ
EA201400333A1 (ru) Бензонитрильные производные в качестве ингибиторов киназ
MA38050A1 (fr) Inhibiteurs de gdf-8
ATE542813T1 (de) 6-substituierte 2- heterocyclylaminopyrazinverbindungen als chk-1- inhibitoren
UA109921C2 (uk) ІМІДАЗО[4,5-c]ХІНОЛІН-2-ОН І ЙОГО ЗАСТОСУВАННЯ ЯК ПОДВІЙНОГО ІНГІБІТОРУ PІ3-КІНАЗИ/mTOR
UA107652C2 (en) Carbazole compounds and therapeutic uses of the compounds
RS53179B (en) BENZODIAZEPINSKI INHIBITOR BROMODOMENA
EA201391165A1 (ru) Пиридинил- и пиразинил-метилоксиарильные производные, полезные в качестве ингибиторов селезеночной тирозинкиназы (syk)
UA111382C2 (uk) Інгібітори протеїнкінази
EA201100580A1 (ru) Имидазопиридазинкарбонитрилы, используемые в качестве ингибиторов киназы
EA201100334A1 (ru) Бициклические производные триазола для лечения опухолей
EA201101533A1 (ru) Гетероциклические соединения в качестве ингибиторов mek
UA85087C2 (en) Monocyclic heterocycles as kinase inhibitors
EA201301301A1 (ru) Производные тиазола
EA200970669A1 (ru) Производные 2-амино-5,7-дигидро-6н-пирроло[3,4-d]пиримидина в качестве ингибиторов hsp-90, предназначенные для лечения рака
EA201100296A1 (ru) Новые фениламино-изоникотинамидные соединения
EA201270816A1 (ru) Производные бензамида и их применение в качестве ингибиторов hsp90